Cannabis Use Disorder (CUD)  Market  is a psychiatric condition involving compulsive cannabis use leading to significant impairment or distress, classified under substance use disorders in the DSM-5. Severity ranges from mild to severe based on symptoms, with treatment typically combining behavioral therapies, counseling, and support groups to address impaired functioning, tolerance, and withdrawal.

For a detailed sample PDF brochure of the report, use a corporate email ID for a quick response: Download Sample PDF.

https://www.datamintelligence.com/download-sample/cannabis-use-disorder-market?sindhuri

Market Segmentation

• By Severity: Mild, Severe

• By Treatment: Detoxification, Counselling & Behavioral Therapy, Medications, Support Group

• By End User: Hospitals and Clinics, Rehabilitation Centers, Others

• By Region: North America, Europe, Asia-Pacific, South America, Middle East & Africa

Market Share

North America holds the largest market share, approximately 42.4% in 2022, driven by high cannabis availability (legal and illicit), lifetime use among about 78 million Americans, and societal normalization leading to increased CUD prevalence. Asia-Pacific is expected to witness the fastest growth due to rising awareness, expanding healthcare access, and shifting attitudes toward substance use disorders.

Market Drivers

The market is propelled by strategic company initiatives, such as partnerships and research funding, enhancing treatment access. For instance, in September 2023, Spring Health partnered with Eleanor Health to expand SUD support services, addressing mental health gaps. In October 2023, Rangiwaho Marae and Rua Bioscience secured New Zealand's first psilocybin license for treating substance use disorders. Additionally, the NIH awarded USD 4 million in 2021 to Johns Hopkins for studying addiction treatments. However, restraints include limited treatment options, with no FDA-approved medications for CUD and variable effectiveness of off-label therapies or behavioral interventions.

Key Players

Prominent companies in the cannabis use disorder market include:

• Indivior PLC

• Teva Pharmaceutical Industries Ltd

• Mylan N.V.

• LGM Pharma

• Pfizer Inc

• F. Hoffmann-La Roche Ltd

• Unichem Labs

• Alkermes plc

• BioCorRx Inc

• Bausch Health Companies, Inc

Recent Developments

• In September 2023, Spring Health partnered with Eleanor Health to provide tailored SUD care, integrating mental health support.

• In October 2023, Rangiwaho Marae and Rua Bioscience obtained New Zealand's first psilocybin cultivation license to treat methamphetamine and other substance use disorders in collaboration with Māori healers and the University of Auckland.

• In 2021, the US NIH granted approximately USD 4 million to Johns Hopkins University for research on drug impacts for tobacco addiction, relevant to broader SUD strategies.

Conclusion

The cannabis use disorder market is set for growth amid increasing cannabis use and societal acceptance, particularly in North America, while Asia-Pacific emerges as a high-potential region through healthcare advancements. Company strategies like partnerships and innovative licensing bolster treatment options, though challenges from limited FDA-approved therapies persist. With behavioral therapy leading at 39.7% share and ongoing research, the market will play a vital role in addressing rising CUD prevalence and co-occurring mental health issues through 2031 and beyond.

About DataM Intelligence

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us

Company Name: DataM Intelligence 4Market Research LLP

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com